ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2555

Addressing Economic Insecurities Could Improve Patient-Reported Outcomes in Lupus
Abstract Number: 0768

Addressing Gaps in Polymyalgia Rheumatica: A Systematic Literature Review
Abstract Number: 1402

Addressing Unmet Needs in Cannabis and Hemp by Improving Knowledge and Data Collection
Abstract Number: 0023

Adenosine and Guanosine-based Oligonucleotide Attenuates Catabolic Phenotypes in Chondrocytes and Slows Progression of Surgically Induced Osteoarthritis
Abstract Number: 1613

Adherence to Dietary Recommendations and the Risk of Developing Giant Cell Arteritis; A Nested Case-Control Study
Abstract Number: 2409

Adherence to EULAR Recommendations and Sub Optimal Management of Systemic Lupus Erythematosus in a Network of Community-Based Rheumatology Practices in the United States
Abstract Number: 2663

ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications
Abstract Number: 0244

Adjunctive Belimumab Exerts Favorable Ferritin Recovery and Survival for Post-COVID Interstitial Lung Disease in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab: A Case Series
Abstract Number: 1920

Admixture Mapping and Gene-Based Analysis Identifies Rare Variants in Genes in the IL-13 and TGFβ Signaling Pathways in African Americans with Systemic Sclerosis
Abstract Number: 0370

Adolescents’ and Providers’ Perceptions of the Transition from Pediatric to Adult Rheumatology
Abstract Number: 1739

Adult and Pediatric Rheumatology Fellow Education on Temporomandibular Joint (TMJ) Arthritis in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 1967

Advanced Imaging in the Evaluation of Lupus Arthritis: A Systematic Literature Review and Meta-Analysis
Abstract Number: 1259

Adverse Childhood Experiences Are Associated with Patient-Reported Outcomes in Adolescents and Young Adults with Systemic Lupus
Abstract Number: 0749

Age at Disease Onset Influences the Clinical Phenotype and Outcome of Patients with Takayasu Arteritis: Results from a Monocentric Cohort of 167 Patients
Abstract Number: 2224

Age of Onset of Rheumatoid Arthritis and Radiographic Changes

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].